Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $875

Benzinga Newsdesk www.benzinga.com Negative 53.2%

Neg 53.2% Neu 0% Pos 0%

Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $1057 to $875.